IP Verse

Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer Treatment - EP3337467

The patent EP3337467 was granted to Ipsen Biopharm on Dec 9, 2020. The application was originally filed on Aug 19, 2016 under application number EP16757498A. The patent is currently recorded with a legal status of "Revoked".

EP3337467

IPSEN BIOPHARM
Application Number
EP16757498A
Filing Date
Aug 19, 2016
Status
Revoked
Aug 11, 2023
Grant Date
Dec 9, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZSep 9, 2021LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBB -

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Alexander Koshkaryev, Jonathan Fitzgerald, Jaeyeon Kim, Ashish Kalra, Walid Kamoun, Sarah Blanchette, Lia Luus, Stephan Klinz, Ozan Alkan, Tad Kornaga, Susan Bates, Yves Pommier and Daryl C. Drummond, "Abstract 2075: Differential tissue clearance results in improved therapeutic index for irinotecan liposome injection (ONIVYDE) when combined with the PARP inhibitor veliparib in preclinical cervical tumors", Cancer Res., New Orleans, LA, (20160000), vol. 76, no. 14, pages 1 - 2, XP055844961-
OPPOSITION- Anonymous, "Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", Protocol of clinical study NCT02631733, (20151215), pages 1 - 7, XP055844955-
OPPOSITION- Anonymous, "Onivyde prescribing information", Onivyde, (20151000), pages 1 - 18, XP055844932-
OPPOSITION- Anonymous, "Pilot Study to Determine Biodistribution of MM-398 and Feasibility of Ferumoxytol as a Tumor Imaging Agent", Protocol of clinical study NCT01770353, (20150505), pages 1 - 6, XP055844919-
OPPOSITION- Irimie Alexandru, Et Al, "Multiple Primary Malignancies - Epidemiological Analysis at a Single Tertiary Institution", J. Gastrointestin Liver Dis., (20100301), vol. 19, no. 1, pages 69 - 73, XP093032756-
OPPOSITION- J. CARNEVALE et al., "MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer", Fut. Oncol., (20160000), vol. 12, no. 4, pages 453 - 464, XP055820804-
OPPOSITION- LORUSSO, P. et al., "Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors", ASCO Annual Meeting, (20110000), pages 1 - 37-
OPPOSITION- O'SULLIVAN, C. et al., "Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors", Front. Oncol., (20140000), vol. 4, no. 42, pages 1 - 13, XP055844926-
OPPOSITION- Patricia M. LoRusso, Jing Li, Angelika Burger, Lance K. Heilbrun, Edward A. Sausville, Scott A. Boerner, Daryn Smith, Mary Jo Pilat, Jie Zhang, Sara M. Tolaney, James M. Cleary, Alice P. Chen, Lawrence Rubinstein, Julie L. Boerner, Adam Bowditch, Dongpo Cai, Tracy Bell, Andrew Wolanski, Allison M. Marrero, Yiping Zhang, Jiuping Ji, Katherine Ferry-Galow, Robert J. Kinders, Ralph E. Parchment and Geoffrey I. Shapiro, "Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors", J. Clin. Oncol., (20110000), vol. 29, no. 15, pages 1 - 15, XP055844897-
OPPOSITION- SHAH, M.A. et al., "The relevance of drug sequence in combination chemotherapy", Drug Resist. Updat., (20000000), vol. 3, pages 335 - 356, XP055844921-
OPPOSITION- Neijzen Robert; Wong May Q; Gill Navdeep; Wang He; Karim Tamanna; Anantha Malathi; Strutt Dita; Waterhouse Dawn; Bally Marcel B; Tai Isabella T; Ng Sylvia S W; Yapp Donald T, "Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer", J. Control. Release, (20150000), vol. 199, pages 72 - 83, XP029190817
OPPOSITION- Berlin Jordan; Ramanathan Ramesh K; Strickler John H; Subramaniam Deepa S; Marshall John; Kang Yoon-Koo; Hetman Robert; Dudley Matthew W; Zeng Jiewei; Nickner Caroline; Xiong Hao; Komarnitsky Philip; Shepherd Stacie Peacock; Hurwitz Herbert; Lenz Heinz-Josef, "A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors", J. Clin. One., (20140000), vol. 32, no. 15S, pages 1 - 4, XP036871195
OPPOSITION- Makiko Tahara; Takeshi Inoue; Futoshi Sato; Yasuyuki Miyakura; Hisanaga Horie; Yoshikazu Yasuda; Hirofumi Fujii; Kenjiro Kotake; Kokichi Sugano, "The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks", Mol. Cancer Ther., (20140000), vol. 13, no. 5, pages 1170 - 1180, XP055746159
OPPOSITION- Feng Li;Wen-Zhao Zhong;Fei-Yu Niu;Ning Zhao;Jin-Ji Yang;Hong-Hong Yan;Yi-Long Wu, "Multiple primary malignancies involving lung cancer", BMC Cancer, LONDON, GB , (20151014), vol. 15, no. 1, doi:10.1186/s12885-015-1733-8, ISSN 1471-2407, page 696, XP021229832
OPPOSITION- LIVRAGHI, L. et al., "PARP inhibitors in the management of breast cancer: current data and future prospects", BMC Med, (20150000), vol. 13, no. 188, pages 1 - 16, XP021227264

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents